leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 00:30:05 - browse：33175

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Medtronic CEO on promising devices for diabetes, hypertension

WSS

Researchers on aging grapple with how to calculate biological age

Brain worms: The science behind RFK Jr.'s parasitic infection

Making AI in medicine accessible to smaller, and rural hospitals

Elevance, private equity launch primary care company

Researchers on aging grapple with how to calculate biological age

Biden's order seeks to regulate AI risk without stifling innovation

entertainment

leisure time

entertainment

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Wildfire smoke exposes gaps in outdoor worker protections

After gene therapy, two congenitally deaf children hear for the first time

Trump demands the U.S. pay no more for drugs than other countries … again

After gene therapy, two congenitally deaf children hear for the first time

Medicare details structure of new drug price negotiation program

The pink breast cancer awareness ribbon needs a redesign

Alkermes shareholders re

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Wikipedia

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Medtronic CEO on promising devices for diabetes, hypertension

Traditional Chinese medicine benefits explored in new JAMA study

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Diversifying clinical trials isn't enough to close racial gaps: study

Cassava reveals details — and problems — with Alzheimer's study

focus

explore

focus

explore